OS Therapies Inc (NYSE:OSTX - Get Free Report)'s share price was down 2.8% during mid-day trading on Friday . The company traded as low as $2.01 and last traded at $2.05. Approximately 392,899 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 706,120 shares. The stock had previously closed at $2.11.
Analyst Upgrades and Downgrades
Separately, D. Boral Capital reissued a "buy" rating and issued a $20.00 target price on shares of OS Therapies in a research report on Friday, September 12th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $18.00.
Check Out Our Latest Report on OSTX
OS Therapies Stock Performance
The stock has a market capitalization of $64.87 million and a P/E ratio of -2.59. The business has a fifty day simple moving average of $2.06 and a 200-day simple moving average of $1.81.
Hedge Funds Weigh In On OS Therapies
Large investors have recently modified their holdings of the company. Bridgeway Capital Management LLC bought a new position in shares of OS Therapies in the 2nd quarter worth $47,000. XTX Topco Ltd purchased a new stake in OS Therapies in the 2nd quarter valued at $63,000. Finally, CM Management LLC raised its position in OS Therapies by 172.6% in the 1st quarter. CM Management LLC now owns 300,000 shares of the company's stock valued at $462,000 after buying an additional 189,956 shares during the last quarter.
About OS Therapies
(
Get Free Report)
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OS Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OS Therapies wasn't on the list.
While OS Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
